<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36012668</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>16</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>20</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>4-Phenylbutyric Acid (4-PBA) Derivatives Prevent SOD1 Amyloid Aggregation In Vitro with No Effect on Disease Progression in SOD1-ALS Mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9403</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23169403</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the degeneration of motor neurons. Mutations in the superoxide dismutase (SOD1) gene, causing protein misfolding and aggregation, were suggested as the pathogenic mechanisms involved in familial ALS cases. In the present study, we investigated the potential therapeutic effect of C4 and C5, two derivatives of the chemical chaperone 4-phenylbutyric acid (4-PBA). By combining in vivo and in vitro techniques, we show that, although C4 and C5 successfully inhibited amyloid aggregation of recombinant mutant SOD1 in a dose-dependent manner, they failed to suppress the accumulation of misfolded SOD1. Moreover, C4 or C5 daily injections to SOD1<sup>G93A</sup> mice following onset had no effect on either the accumulation of misfolded SOD1 or the neuroinflammatory response in the spinal cord and, consequently, failed to extend the survival of SOD1<sup>G93A</sup> mice or to improve their motor symptoms. Finally, pharmacokinetic (PK) studies demonstrated that high concentrations of C4 and C5 reached the brain and spinal cord but only for a short period of time. Thus, our findings suggest that use of such chemical chaperones for ALS drug development may need to be optimized for more effective results.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alfahel</LastName><ForeName>Leenor</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology and The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, P.O. Box 653, Beer Sheva 8410501, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Argueti-Ostrovsky</LastName><ForeName>Shirel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology and The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, P.O. Box 653, Beer Sheva 8410501, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barel</LastName><ForeName>Shir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology and The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, P.O. Box 653, Beer Sheva 8410501, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali Saleh</LastName><ForeName>Mahmood</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology and The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, P.O. Box 653, Beer Sheva 8410501, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Joy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology and The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, P.O. Box 653, Beer Sheva 8410501, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azoulay-Ginsburg</LastName><ForeName>Salome</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9140-5331</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Exact Sciences, Campus Ramat-Gan, Bar-Ilan University, Ramat-Gan 5290002, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>Ayelet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Exact Sciences, Campus Ramat-Gan, Bar-Ilan University, Ramat-Gan 5290002, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebbinghaus</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Physical and Theoretical Chemistry, TU Braunschweig, Rebenring 56, 38106 Braunschweig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruzman</LastName><ForeName>Arie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Exact Sciences, Campus Ramat-Gan, Bar-Ilan University, Ramat-Gan 5290002, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Israelson</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8289-7653</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology and The Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, P.O. Box 653, Beer Sheva 8410501, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I-5-201.6-2016</GrantID><Agency>German-Israeli Foundation for Scientific Research and Development</Agency><Country/></Grant><Grant><GrantID># 284/19</GrantID><Agency>Israel Science Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C121358">4-phenylbutylamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058227">Amyloidogenic Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002082">Butylamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010654">Phenylbutyrates</NameOfSubstance></Chemical><Chemical><RegistryNumber>7WY7YBI87E</RegistryNumber><NameOfSubstance UI="C075773">4-phenylbutyric acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058227" MajorTopicYN="N">Amyloidogenic Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002082" MajorTopicYN="N">Butylamines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010654" MajorTopicYN="N">Phenylbutyrates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aggregation</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">chemical chaperones</Keyword><Keyword MajorTopicYN="N">misfolded proteins</Keyword><Keyword MajorTopicYN="N">mutant SOD1</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36012668</ArticleId><ArticleId IdType="pmc">PMC9409193</ArticleId><ArticleId IdType="doi">10.3390/ijms23169403</ArticleId><ArticleId IdType="pii">ijms23169403</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Israelson A., Ditsworth D., Sun S., Song S., Liang J., Hruska-Plochan M., McAlonis-Downes M., Abu-Hamad S., Zoltsman G., Shani T., et al. Macrophage Migration Inhibitory Factor as a Chaperone Inhibiting Accumulation of Misfolded SOD. Neuron. 2015;86:218&#x2013;232. doi: 10.1016/j.neuron.2015.02.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.02.034</ArticleId><ArticleId IdType="pmc">PMC4393372</ArticleId><ArticleId IdType="pubmed">25801706</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz S., Cleveland D.W. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr. Opin. Neurobiol. 2011;21:904&#x2013;919. doi: 10.1016/j.conb.2011.05.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2011.05.029</ArticleId><ArticleId IdType="pmc">PMC3228892</ArticleId><ArticleId IdType="pubmed">21813273</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.-X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G., Gautier O., Tassoni-Tsuchida E., Ma X.R., Gitler A.D. ALS Genetics: Gains, Losses, and Implications for Future Therapies. Neuron. 2020;108:822&#x2013;842. doi: 10.1016/j.neuron.2020.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee V., Shani T., Katzman B., Vyazmensky M., Papo N., Israelson A., Engel S. Superoxide Dismutase 1 (SOD1)-Derived Peptide Inhibits Amyloid Aggregation of Familial Amyotrophic Lateral Sclerosis SOD1 Mutants. ACS Chem. Neurosci. 2016;7:1595&#x2013;1606. doi: 10.1021/acschemneuro.6b00227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.6b00227</ArticleId><ArticleId IdType="pubmed">27540759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Miller T.M., Cleveland D.W. Unraveling the Mechanisms Involved in Motor Neuron Degeneration in ALS. Annu. Rev. Neurosci. 2004;27:723&#x2013;749. doi: 10.1146/annurev.neuro.27.070203.144244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.27.070203.144244</ArticleId><ArticleId IdType="pubmed">15217349</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N., Hirano A., Kobayashi M., Siddique T., Deng H.-X., Hung W.-Y., Kato T., Asayama K. Intense Superoxide Dismutase-1 Immunoreactivity in Intracytoplasmic Hyaline Inclusions of Familial Amyotrophic Lateral Sclerosis with Posterior Column Involvement. J. Neuropathol. Exp. Neurol. 1996;55:481&#x2013;490. doi: 10.1097/00005072-199604000-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199604000-00011</ArticleId><ArticleId IdType="pubmed">8786408</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg K., Andersen P.M., Marklund S.L., Br&#xe4;nnstr&#xf6;m T. Glial nuclear aggregates of superoxide dismutase-1 are regularly present in patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2011;121:623&#x2013;634. doi: 10.1007/s00401-011-0805-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0805-3</ArticleId><ArticleId IdType="pmc">PMC3085063</ArticleId><ArticleId IdType="pubmed">21287393</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Becher M.W., Lee M.K., Anderson K.L., Jenkins N.A., Copeland N.G., Sisodia S.S., Rothstein J.D., Borchelt D.R., Price D.L., et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18:327&#x2013;338. doi: 10.1016/S0896-6273(00)80272-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80272-X</ArticleId><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M., Dykes-Hoberg M., Cizewski Culotta V., Price D.L., Wong P.C., Rothstein J.D. Histological Evidence of Protein Aggregation in Mutant SOD1 Transgenic Mice and in Amyotrophic Lateral Sclerosis Neural Tissues. Neurobiol. Dis. 2001;8:933&#x2013;941. doi: 10.1006/nbdi.2001.0443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2001.0443</ArticleId><ArticleId IdType="pubmed">11741389</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Hamad S., Kahn J., Leyton-Jaimes M.F., Rosenblatt J., Israelson A. Misfolded SOD1 Accumulation and Mitochondrial Association Contribute to the Selective Vulnerability of Motor Neurons in Familial ALS: Correlation to Human Disease. ACS Chem. Neurosci. 2017;8:2225&#x2013;2234. doi: 10.1021/acschemneuro.7b00140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.7b00140</ArticleId><ArticleId IdType="pubmed">28715630</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Johnson J.L., Agar N.Y.R., Agar J.N. Protein Aggregation and Protein Instability Govern Familial Amyotrophic Lateral Sclerosis Patient Survival. PLoS Biol. 2008;6:e170. doi: 10.1371/journal.pbio.0060170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0060170</ArticleId><ArticleId IdType="pmc">PMC2486295</ArticleId><ArticleId IdType="pubmed">18666828</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori A., Yamashita S., Uchino K., Suga T., Ikeda T., Takamatsu K., Ishizaki M., Koide T., Kimura E., Mita S., et al. Derlin-1 overexpression ameliorates mutant SOD1-induced endoplasmic reticulum stress by reducing mutant SOD1 accumulation. Neurochem. Int. 2010;58:344&#x2013;353. doi: 10.1016/j.neuint.2010.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2010.12.010</ArticleId><ArticleId IdType="pubmed">21185345</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishitoh H., Kadowaki H., Nagai A., Maruyama T., Yokota T., Fukutomi H., Noguchi T., Matsuzawa A., Takeda K., Ichijo H. ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev. 2008;22:1451&#x2013;1464. doi: 10.1101/gad.1640108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1640108</ArticleId><ArticleId IdType="pmc">PMC2418582</ArticleId><ArticleId IdType="pubmed">18519638</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.-X., Shi Y., Furukawa Y., Zhai H., Fu R., Liu E., Gorrie G.H., Khan M.S., Hung W.-Y., Bigio E.H., et al. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc. Natl. Acad. Sci. USA. 2006;103:7142&#x2013;7147. doi: 10.1073/pnas.0602046103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0602046103</ArticleId><ArticleId IdType="pmc">PMC1447523</ArticleId><ArticleId IdType="pubmed">16636275</ArticleId></ArticleIdList></Reference><Reference><Citation>Israelson A., Arbel N., Da Cruz S., Ilieva H., Yamanaka K., Shoshan-Barmatz V., Cleveland D.W. Misfolded Mutant SOD1 Directly Inhibits VDAC1 Conductance in a Mouse Model of Inherited ALS. Neuron. 2010;67:575&#x2013;587. doi: 10.1016/j.neuron.2010.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.07.019</ArticleId><ArticleId IdType="pmc">PMC2941987</ArticleId><ArticleId IdType="pubmed">20797535</ArticleId></ArticleIdList></Reference><Reference><Citation>Shteinfer-Kuzmine A., Argueti S., Gupta R., Shvil N., Abu-Hamad S., Gropper Y., Hoeber J., Magr&#xec; A., Messina A., Kozlova E.N., et al. A VDAC1-Derived N-Terminal Peptide Inhibits Mutant SOD1-VDAC1 Interactions and Toxicity in the SOD1 Model of ALS. Front. Cell. Neurosci. 2019;13:346. doi: 10.3389/fncel.2019.00346.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00346</ArticleId><ArticleId IdType="pmc">PMC6702328</ArticleId><ArticleId IdType="pubmed">31474832</ArticleId></ArticleIdList></Reference><Reference><Citation>Banci L., Bertini I., Boca M., Girotto S., Martinelli M., Valentine J.S., Vieru M. SOD1 and Amyotrophic Lateral Sclerosis: Mutations and Oligomerization. PLoS ONE. 2008;3:e1677. doi: 10.1371/journal.pone.0001677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001677</ArticleId><ArticleId IdType="pmc">PMC2250751</ArticleId><ArticleId IdType="pubmed">18301754</ArticleId></ArticleIdList></Reference><Reference><Citation>Elam J.S., Taylor A.B., Strange R., Antonyuk S., Doucette P.A., Rodriguez J.A., Hasnain S.S., Hayward L.J., Valentine J.S., Yeates T., et al. Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS. Nat. Struct. Mol. Biol. 2003;10:461&#x2013;467. doi: 10.1038/nsb935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsb935</ArticleId><ArticleId IdType="pubmed">12754496</ArticleId></ArticleIdList></Reference><Reference><Citation>Durer Z.A.O., Cohlberg J.A., Dinh P., Padua S., Ehrenclou K., Downes S., Tan J.K., Nakano Y., Bowman C.J., Hoskins J.L., et al. Loss of Metal Ions, Disulfide Reduction and Mutations Related to Familial ALS Promote Formation of Amyloid-Like Aggregates from Superoxide Dismutase. PLoS ONE. 2009;4:e5004. doi: 10.1371/journal.pone.0005004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0005004</ArticleId><ArticleId IdType="pmc">PMC2659422</ArticleId><ArticleId IdType="pubmed">19325915</ArticleId></ArticleIdList></Reference><Reference><Citation>Shvil N., Banerjee V., Zoltsman G., Shani T., Kahn J., Abu-Hamad S., Papo N., Engel S., Bernhagen J., Israelson A. MIF inhibits the formation and toxicity of misfolded SOD1 amyloid aggregates: Implications for familial ALS. Cell Death Dis. 2018;9:107. doi: 10.1038/s41419-017-0130-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-017-0130-4</ArticleId><ArticleId IdType="pmc">PMC5833700</ArticleId><ArticleId IdType="pubmed">29371591</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg K., Graffmo K., Pakkenberg B., Weber M., Nielsen M., Marklund S., Br&#xe4;nnstr&#xf6;m T., Andersen P.M. Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS/FTD-associated genes. J. Neurol. Neurosurg. Psychiatry. 2019;90:861&#x2013;869. doi: 10.1136/jnnp-2018-319386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319386</ArticleId><ArticleId IdType="pmc">PMC6691870</ArticleId><ArticleId IdType="pubmed">30992335</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad L.I., Yerbury J.J., Turner B.J., Guest W.C., Pokrishevsky E., O&#x2019;Neill M.A., Yanai A., Silverman J.M., Zeineddine R., Corcoran L., et al. Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. USA. 2014;111:3620&#x2013;3625. doi: 10.1073/pnas.1312245111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1312245111</ArticleId><ArticleId IdType="pmc">PMC3948312</ArticleId><ArticleId IdType="pubmed">24550511</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., Reaume A.G., Scott R.W., Cleveland D.W. Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1. Science. 1998;281:1851&#x2013;1854. doi: 10.1126/science.281.5384.1851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.281.5384.1851</ArticleId><ArticleId IdType="pubmed">9743498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Xu G., Gonzales V., Coonfield M., Fromholt D., Copeland N.G., Jenkins N.A., Borchelt D.R. Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site. Neurobiol. Dis. 2002;10:128&#x2013;138. doi: 10.1006/nbdi.2002.0498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2002.0498</ArticleId><ArticleId IdType="pubmed">12127151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmar B., Greensmith L. Cellular Chaperones As Therapeutic Targets in ALS to Restore Protein Homeostasis and Improve Cellular Function. Front. Mol. Neurosci. 2017;10:251. doi: 10.3389/fnmol.2017.00251.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00251</ArticleId><ArticleId IdType="pmc">PMC5596081</ArticleId><ArticleId IdType="pubmed">28943839</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira D.M., Valent&#xe3;o P., Andrade P.B. Tuning protein folding in lysosomal storage diseases: The chemistry behind pharmacological chaperones. Chem. Sci. 2018;9:1740&#x2013;1752. doi: 10.1039/C7SC04712F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C7SC04712F</ArticleId><ArticleId IdType="pmc">PMC5896381</ArticleId><ArticleId IdType="pubmed">29719681</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Macklin E.A., Hendrix S., Berry J.D., Elliott M.A., Maiser S., Karam C., Caress J.B., Owegi M.A., Quick A., et al. Trial of Sodium Phenylbutyrate&#x2013;Taurursodiol for Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2020;383:919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Hendrix S., Dickson S.P., Ms N.K., Macklin E.A., Berry J.D., Elliott M.A., Maiser S., Karam C., Caress J.B., et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2020;63:31&#x2013;39. doi: 10.1002/mus.27091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27091</ArticleId><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortez L., Sim V. The therapeutic potential of chemical chaperones in protein folding diseases. Prion. 2014;8:197&#x2013;202. doi: 10.4161/pri.28938.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/pri.28938</ArticleId><ArticleId IdType="pmc">PMC4189890</ArticleId><ArticleId IdType="pubmed">24818993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley J.C., Pettan-Brewer C., Ladiges W.C. Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice. Aging Cell. 2011;10:418&#x2013;428. doi: 10.1111/j.1474-9726.2011.00680.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2011.00680.x</ArticleId><ArticleId IdType="pubmed">21272191</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardian G., Browne S.E., Choi D.-K., Klivenyi P., Gregorio J., Kubilus J.K., Ryu H., Langley B., Ratan R.R., Ferrante R.J., et al. Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington&#x2019;s Disease. J. Biol. Chem. 2005;280:556&#x2013;563. doi: 10.1074/jbc.M410210200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M410210200</ArticleId><ArticleId IdType="pubmed">15494404</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoulay-Ginsburg S., Trobiani L., Setini A., Favaloro F.L., Giorda E., Jacob A., Hauschner H., Levy L., Cestra G., De Jaco A., et al. A Lipophilic 4-Phenylbutyric Acid Derivative That Prevents Aggregation and Retention of Misfolded Proteins. Chemistry. 2019;26:1834&#x2013;1845. doi: 10.1002/chem.201904292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/chem.201904292</ArticleId><ArticleId IdType="pubmed">31773792</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoulay-Ginsburg S., Di Salvio M., Weitman M., Afri M., Ribeiro S., Ebbinghaus S., Cestra G., Gruzman A. Chemical chaperones targeted to the endoplasmic reticulum (ER) and lysosome prevented neurodegeneration in a C9orf72 repeat expansion drosophila amyotrophic lateral sclerosis (ALS) model. Pharmacol. Rep. 2021;73:536&#x2013;550. doi: 10.1007/s43440-021-00226-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-021-00226-2</ArticleId><ArticleId IdType="pubmed">33661518</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N.-Y., Kang Y.-S. In Vivo and In Vitro Evidence for Brain Uptake of 4-Phenylbutyrate by the Monocarboxylate Transporter 1 (MCT1) Pharm. Res. 2016;33:1711&#x2013;1722. doi: 10.1007/s11095-016-1912-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-016-1912-6</ArticleId><ArticleId IdType="pubmed">27026010</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Kankel M.W., Su S.C., Han S.W.S., Ofengeim D. Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD. Cell Death Differ. 2018;25:648&#x2013;662. doi: 10.1038/s41418-018-0060-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-018-0060-4</ArticleId><ArticleId IdType="pmc">PMC5864209</ArticleId><ArticleId IdType="pubmed">29459769</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Harten A.C., Phatnani H., Przedborski S. Non-cell-autonomous pathogenic mechanisms in amyotrophic lateral sclerosis. Trends Neurosci. 2021;44:658&#x2013;668. doi: 10.1016/j.tins.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8972039</ArticleId><ArticleId IdType="pubmed">34006386</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M., Re D., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007;10:615&#x2013;622. doi: 10.1038/nn1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1876</ArticleId><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Cagnin A., Turkheimer F.E., Miller C.C.J., Shaw C.E., Brooks D.J., Leigh P.N., Banati R.B. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 2004;15:601&#x2013;609. doi: 10.1016/j.nbd.2003.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2003.12.012</ArticleId><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyton-Jaimes M.F., Benaim C., Abu-Hamad S., Kahn J., Guetta A., Bucala R., Israelson A. Endogenous macrophage migration inhibitory factor reduces the accumulation and toxicity of misfolded SOD1 in a mouse model of ALS. Proc. Natl. Acad. Sci. USA. 2016;113:10198&#x2013;10203. doi: 10.1073/pnas.1604600113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1604600113</ArticleId><ArticleId IdType="pmc">PMC5018779</ArticleId><ArticleId IdType="pubmed">27551074</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyton-Jaimes M.F., Kahn J., Israelson A. AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS. Proc. Natl. Acad. Sci. USA. 2019;116:14755&#x2013;14760. doi: 10.1073/pnas.1904665116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1904665116</ArticleId><ArticleId IdType="pmc">PMC6642395</ArticleId><ArticleId IdType="pubmed">31262807</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia N.K., Srivastava A., Katyal N., Jain N., Khan M.A.I., Kundu B., Deep S. Curcumin binds to the pre-fibrillar aggregates of Cu/Zn superoxide dismutase (SOD1) and alters its amyloidogenic pathway resulting in reduced cytotoxicity. Biochim. Biophys. Acta. 2015;1854:426&#x2013;436. doi: 10.1016/j.bbapap.2015.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2015.01.014</ArticleId><ArticleId IdType="pubmed">25666897</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross C.A., Poirier M.A. What is the role of protein aggregation in neurodegeneration? Nat. Rev. Mol. Cell Biol. 2005;6:891&#x2013;898. doi: 10.1038/nrm1742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm1742</ArticleId><ArticleId IdType="pubmed">16167052</ArticleId></ArticleIdList></Reference><Reference><Citation>Carija A., Navarro S., de Groot N.S., Ventura S. Protein aggregation into insoluble deposits protects from oxidative stress. Redox Biol. 2017;12:699&#x2013;711. doi: 10.1016/j.redox.2017.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.03.027</ArticleId><ArticleId IdType="pmc">PMC5390671</ArticleId><ArticleId IdType="pubmed">28410533</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefani M. Protein misfolding and aggregation: New examples in medicine and biology of the dark side of the protein world. Biochim. Biophys. Acta. 2004;1739:5&#x2013;25. doi: 10.1016/j.bbadis.2004.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2004.08.004</ArticleId><ArticleId IdType="pubmed">15607113</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefani M., Dobson C.M. Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 2003;81:678&#x2013;699. doi: 10.1007/s00109-003-0464-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-003-0464-5</ArticleId><ArticleId IdType="pubmed">12942175</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsellier E., Ramazzotti M., Taddei N., Chiti F. Aggregation Propensity of the Human Proteome. PLoS Comput. Biol. 2008;4:e1000199. doi: 10.1371/journal.pcbi.1000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1000199</ArticleId><ArticleId IdType="pmc">PMC2557143</ArticleId><ArticleId IdType="pubmed">18927604</ArticleId></ArticleIdList></Reference><Reference><Citation>Fassler J.S., Skuodas S., Weeks D.L., Phillips B.T. Protein Aggregation and Disaggregation in Cells and Development. J. Mol. Biol. 2021;433:167215. doi: 10.1016/j.jmb.2021.167215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2021.167215</ArticleId><ArticleId IdType="pmc">PMC8530975</ArticleId><ArticleId IdType="pubmed">34450138</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad S., Cereghetti G., Feng Y., Picotti P., Peter M., DeChant R. Reversible protein aggregation is a protective mechanism to ensure cell cycle restart after stress. Nat. Cell Biol. 2017;19:1202&#x2013;1213. doi: 10.1038/ncb3600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3600</ArticleId><ArticleId IdType="pubmed">28846094</ArticleId></ArticleIdList></Reference><Reference><Citation>Hnath B., Dokholyan N.V. Toxic SOD1 trimers are off-pathway in the formation of amyloid-like fibrils in ALS. Biophys. J. 2022;121:2084&#x2013;2095. doi: 10.1016/j.bpj.2022.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9247475</ArticleId><ArticleId IdType="pubmed">35505609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu C., Beck M.V., Griffith J.D., Deshmukh M., Dokholyan N.V. Large SOD1 aggregates, unlike trimeric SOD1, do not impact cell viability in a model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2018;115:4661&#x2013;4665. doi: 10.1073/pnas.1800187115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1800187115</ArticleId><ArticleId IdType="pmc">PMC5939103</ArticleId><ArticleId IdType="pubmed">29666246</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805&#x2013;810. doi: 10.1038/nature02998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02998</ArticleId><ArticleId IdType="pubmed">15483602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu H., Smith K., Camelo S.I., Carreras I., Lee J., Iglesias A.H., Dangond F., Cormier K.A., Cudkowicz M.E., Brown R.H., et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 2005;93:1087&#x2013;1098. doi: 10.1111/j.1471-4159.2005.03077.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03077.x</ArticleId><ArticleId IdType="pubmed">15934930</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S., Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Crow J.P., Beal M.F. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2006;22:40&#x2013;49. doi: 10.1016/j.nbd.2005.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.09.013</ArticleId><ArticleId IdType="pubmed">16289867</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Signore S.J., Amante D., Kim J., Stack E.C., Goodrich S., Cormier K., Smith K., Cudkowicz M.E., Ferrante R.J. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph. Lateral Scler. 2009;10:85&#x2013;94. doi: 10.1080/17482960802226148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802226148</ArticleId><ArticleId IdType="pubmed">18618304</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Rothstein J.D. Rodent Models of Amyotrophic Lateral Sclerosis. Curr. Protoc. Pharmacol. 2015;69:5.67.1&#x2013;5.67.21. doi: 10.1002/0471141755.ph0567s69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471141755.ph0567s69</ArticleId><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2018;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V., The ALS/Riluzole Study Group A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K., Watanabe K., Yuki S., Akimoto M., Sakata T., Palumbo J. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2017;18:5&#x2013;10. doi: 10.1080/21678421.2017.1353101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1353101</ArticleId><ArticleId IdType="pubmed">28872907</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole But Not Melatonin Ameliorates Acute Motor Neuron Degeneration and Moderately Inhibits SOD1-Mediated Excitotoxicity Induced Disrupted Mitochondrial Ca2+ Signaling in Amyotrophic Lateral Sclerosis. Front. Cell. Neurosci. 2017;10:295. doi: 10.3389/fncel.2016.00295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2016.00295</ArticleId><ArticleId IdType="pmc">PMC5216043</ArticleId><ArticleId IdType="pubmed">28111541</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellingham M.C. A Review of the Neural Mechanisms of Action and Clinical Efficiency of Riluzole in Treating Amyotrophic Lateral Sclerosis: What have we Learned in the Last Decade? CNS Neurosci. Ther. 2011;17:4&#x2013;31. doi: 10.1111/j.1755-5949.2009.00116.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2009.00116.x</ArticleId><ArticleId IdType="pmc">PMC6493865</ArticleId><ArticleId IdType="pubmed">20236142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L., Bensimon G., Leigh P.N., Guillet P., Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425&#x2013;1431. doi: 10.1016/S0140-6736(96)91680-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)91680-3</ArticleId><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg M., Halang L., Woods I., Coughlan K.S., Prehn J.H.M. Riluzole does not improve lifespan or motor function in three ALS mouse models. Amyotroph. Lateral Scler. Front. Degener. 2017;19:438&#x2013;445. doi: 10.1080/21678421.2017.1407796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1407796</ArticleId><ArticleId IdType="pubmed">29221425</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H., Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study) Amyotroph. Lateral Scler. 2006;7:247&#x2013;251. doi: 10.1080/17482960600881870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohta Y., Nomura E., Shang J., Feng T., Huang Y., Liu X., Shi X., Nakano Y., Hishikawa N., Sato K., et al. Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2018;97:607&#x2013;619. doi: 10.1002/jnr.24368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.24368</ArticleId><ArticleId IdType="pubmed">30565312</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H., Wate R., Zhang J., Ohnishi S., Kaneko S., Ito H., Nakano S., Kusaka H. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp. Neurol. 2008;213:448&#x2013;455. doi: 10.1016/j.expneurol.2008.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.07.017</ArticleId><ArticleId IdType="pubmed">18718468</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Deacon R.M. Measuring the Strength of Mice. J. Vis. Exp. 2013;76:e2610. doi: 10.3791/2610.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/2610</ArticleId><ArticleId IdType="pmc">PMC3725666</ArticleId><ArticleId IdType="pubmed">23770643</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros T., Kidd J.D., Moreno A.J., Thompson K., Gill A., Vieira F.G. A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS. J. Vis. Exp. 2015;104:e53257. doi: 10.3791/53257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/53257</ArticleId><ArticleId IdType="pmc">PMC4692639</ArticleId><ArticleId IdType="pubmed">26485052</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakavayev S., Chetrit N., Zvagelsky T., Mansour R., Vyazmensky M., Barak Z., Israelson A., Engel S. Cu/Zn-superoxide dismutase and wild-type like fALS SOD1 mutants produce cytotoxic quantities of H2O2 via cysteine-dependent redox short-circuit. Sci. Rep. 2019;9:10826. doi: 10.1038/s41598-019-47326-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-47326-x</ArticleId><ArticleId IdType="pmc">PMC6658568</ArticleId><ArticleId IdType="pubmed">31346243</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheffield P., Garrard S., Derewenda Z. Overcoming Expression and Purification Problems of RhoGDI Using a Family of &#x201c;Parallel&#x201d; Expression Vectors. Protein Expr. Purif. 1999;15:34&#x2013;39. doi: 10.1006/prep.1998.1003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/prep.1998.1003</ArticleId><ArticleId IdType="pubmed">10024467</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>